Protagonist Therapeutics PTGX Institutional Ownership

Updated Oct 11, 2026

Protagonist Therapeutics, Inc (NASDAQ:PTGX) was held by 344 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Total shares held in Protagonist Therapeutics rose 5.32% versus Q1 2026, while the number of holders rose 27.88% versus Q2 2025.
• Of these 344 holders, 203 added to their positions, 87 reduced their stakes and 54 left their positions unchanged.
• In total, institutional investors held 75.72Mn shares of Protagonist Therapeutics at the end of Q2 2026, up 3.82Mn from the prior quarter and up 5.81Mn from a year earlier.
• BlackRock, Inc. held the largest position in PTGX at 10.31Mn shares as of June 30, 2026.
• The biggest increases in PTGX positions during Q2 2026 came from BlackRock, Inc. (+528.47K shares), T. Rowe Price Associates Inc (+484.17K shares), Franklin Templeton Inc (+382.16K shares), Alyeska Investment Group, L.P. (+296.1K shares) and Lord, Abbett & Co. LLC (+235.53K shares).
• Among holders that kept a stake in Protagonist Therapeutics, the biggest sellers in Q2 2026 were UBS Group AG (-1.78Mn shares), Marshall Wace, LLP (-519.06K shares), Dimensional Fund Advisors LP (-329.95K shares), Perceptive Advisors LLC (-249K shares) and Holocene Advisors, LP (-201.42K shares).
• Business Quant data shows the 10 biggest positions in Protagonist Therapeutics as of Q2 2026 were held by BlackRock, Inc. (10.31Mn shares), Farallon Capital Management, L.L.C. (6.35Mn shares), RTW Investments, LP (5.06Mn shares), Vanguard Portfolio Management LLC (3.63Mn shares), Wellington Management Group LLP (3.42Mn shares), UBS Group AG (3.4Mn shares), State Street Corp (3.32Mn shares), Vanguard Capital Management LLC (2.85Mn shares), Johnson & Johnson (2.45Mn shares) and Invesco Ltd. (2.34Mn shares).